Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TEAD1 | P28347 | 8/20 | 0.41 |
| ▸ | IL1B | P01584 | 6/20 | 0.37 |
| ▸ | NLRP3 | Q96P20 | 2/20 | 0.37 |
| ▸ | ACACB | O00763 | 1/20 | 0.35 |
| ▸ | UBE2M | P61081 | 2/20 | 0.35 |
| ▸ | DCUN1D1 | Q96GG9 | 2/20 | 0.35 |
| ▸ | TAS2R14 | Q9NYV8 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24781071 | 0.80 | TEAD1 (0.45) | TEAD1UBE2MDCUN1D1 | |
| SCHEMBL21958248 | 0.79 | TEAD1 (0.60) | TEAD1 | |
| SCHEMBL24781273 | 0.75 | RHOC (0.40) | TEAD1IL1BUBE2MDCUN1D1 | |
| SCHEMBL21856343 | 0.72 | TAS2R14 (0.37) | TEAD1IL1BNLRP3UBE2MDCUN1D1 | |
| SCHEMBL25785380 | 0.71 | TEAD1 (0.50) | TEAD1 | |
| SCHEMBL21958962 | 0.68 | TEAD1 (0.57) | TEAD1 | |
| SCHEMBL21958174 | 0.68 | TEAD1 (0.57) | TEAD1 | |
| SCHEMBL21958748 | 0.66 | TEAD1 (0.60) | TEAD1 | |
| SCHEMBL21958155 | 0.66 | TEAD1 (0.60) | TEAD1 | |
| SCHEMBL20170132 | 0.62 | GABBR2 (0.36) | IL1BNLRP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220402869-A1 | TRANSCRIPTIONAL ENHANCED ASSOCIATE DOMAIN (TEAD) TRANSCRIPTION FACTOR INHIBITORS AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2022-12-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220402869-A1 | TRANSCRIPTIONAL ENHANCED ASSOCIATE DOMAIN (TEAD) TRANSCRIPTION FACTOR INHIBITORS AND USES THEREOF | TEAD1, TEAD4, TEAD2 | TEAD1 1/4885IL1B 3792/4885NLRP3 1181/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.